The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2026 | Fixed-duration acalabrutinib combinations in CLL
Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, discusses emerging fixed-duration regimens combining acalabrutinib and venetoclax for chronic lymphocytic leukemia (CLL). He highlights how these strategies challenge the paradigm of indefinite BTK inhibitor therapy while maintaining efficacy and improving tolerability. This interview took place at the ESH CLL 2026 congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
